Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 187

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

An 18‐month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis

Open access
Oermann, Christopher M., Retsch‐Bogart, George Z., Quittner, Alexandra L., Gibson, Ronald L., McCoy, Karen S., Montgomery, A. Bruce, Cooper, Peter J. · 2010 · Pediatric Pulmonology

Abstract

Chronic airway infection with Pseudomonas aeruginosa (PA) causes morbidity and mortality in patients with cystic fibrosis (CF). Additional anti‐PA therapies are needed to improve health status and health‐related quality of life. AIR‐CF3 was an international 18‐month, open‐label study to evaluate the safety and efficacy of repeated courses of aztreonam for inhalation solution (AZLI, now marketed as Cayston®) in patients aged ≥6 years with CF and PA infection who previously participated in one of two Phase 3 studies: AIR‐CF1 or AIR‐CF2. Patients received up to nine courses (28 days on/28 days off) of 75 mg AZLI two (BID) or three times daily (TID) based on randomization in the previous trials. 274 patients, mean age 28.5 years (range: 8–74 years), participated. Mean treatment adherence was high (92.0% BID group, 88.0% TID group). Hospitalization rates were low and adverse events were consistent with CF. With each course of AZLI, FEV 1 and scores on the Cystic Fibrosis Questionnaire‐Revised Respiratory Symptom scale improved and bacterial density in sputum was reduced. Benefits waned in the 28 days off therapy, but weight gain was sustained over the 18 months. There were no sustained decreases in PA susceptibility. A dose response was observed; AZLI TID‐treated patients demonstrated greater improvements in lung function and respiratory symptoms over 18 months. Repeated intermittent 28‐day courses of AZLI treatment were well tolerated. Clinical benefits in pulmonary function, health‐related quality of life, and weight were observed with each course of therapy. AZLI is a safe and effective new therapy in patients with CF and PA airway infection. Pediatr Pulmonol. 2010;45:1121–1134. © 2010 Wiley‐Liss, Inc.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ppul.21301

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 187

Metadata

Authors
Oermann, C. M., Retsch‐Bogart, G. Z., Quittner, A. L., Gibson, R. L., McCoy, K. S., Montgomery, A. B., & Cooper, P. J.
Venue
Pediatric Pulmonology
Publisher
Wiley
Published
2010-10-26
Volume
45
Issue
11
Pages
1121-1134
ISSN
  • 1099-0496 (ISSN-L)
  • 8755-6863
OpenAlex
W2010268034
Cited by
187
References
1
FWCI
14.76
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.